18
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Determinants of Behavioral Intentions to Screen for Prostate Cancer in Omani Men

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective:

          This study aimed at exploring the perceived barriers and intention to screen for prostate cancer (PCa).

          Methods:

          A survey questionnaire and a descriptive design were used to collect data from 129 Omani men above the age of 40 years. The questionnaire comprised the International Prostate Symptom Score (IPSS), barriers, and intention to screen scales. The participants were recruited from barbershops located in two cities of Oman.

          Results:

          The mean IPSS score was 8.31 ± 3.34 and the majority of participants had mild prostate cancer symptoms (60.4%). The others had moderate (28.7%) or severe symptoms (10.9%). Most men had low-to-moderate intention to screen using the method of digital rectal examination (DRE) (76%) and prostate-specific antigen test (PSA) (69.8%). The most common barriers to screening were fear of finding out something wrong (48.1%), not knowing what will be done during screening (54.3%), belief that PCa is not a serious disease (55.8%), and belief that DRE is embarrassing (56.6%). The significant determinants of intention to screen using DRE were perceived threat of the disease ( P = 0.006) and past information from doctors that one has any prostate disease ( P = 0.017). The determinants of intention to screen using PSA were perceived threat of the disease ( P = 0.025), perceived general health ( P = 0.047), and past information from doctors that one has any prostate disease ( P = 0.017).

          Conclusions:

          The participants had diminutive intention to undergo PCa screening. Interventions aimed at enhancing PCa disease and risk awareness may help to reduce the barriers and increase PCa screening uptake.

          Related collections

          Most cited references24

          • Record: found
          • Abstract: found
          • Article: not found

          American Cancer Society guideline for the early detection of prostate cancer: update 2010.

          In 2009, the American Cancer Society (ACS) Prostate Cancer Advisory Committee began the process of a complete update of recommendations for early prostate cancer detection. A series of systematic evidence reviews was conducted focusing on evidence related to the early detection of prostate cancer, test performance, harms of therapy for localized prostate cancer, and shared and informed decision making in prostate cancer screening. The results of the systematic reviews were evaluated by the ACS Prostate Cancer Advisory Committee, and deliberations about the evidence occurred at committee meetings and during conference calls. On the basis of the evidence and a consensus process, the Prostate Cancer Advisory Committee developed the guideline, and a writing committee drafted a guideline document that was circulated to the entire committee for review and revision. The document was then circulated to peer reviewers for feedback, and finally to the ACS Mission Outcomes Committee and the ACS Board of Directors for approval. The ACS recommends that asymptomatic men who have at least a 10-year life expectancy have an opportunity to make an informed decision with their health care provider about screening for prostate cancer after they receive information about the uncertainties, risks, and potential benefits associated with prostate cancer screening. Prostate cancer screening should not occur without an informed decision-making process. Men at average risk should receive this information beginning at age 50 years. Men in higher risk groups should receive this information before age 50 years. Men should either receive this information directly from their health care providers or be referred to reliable and culturally appropriate sources. Patient decision aids are helpful in preparing men to make a decision whether to be tested. Copyright 2010 American Cancer Society, Inc.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Screening for prostate cancer

            Cochrane Database of Systematic Reviews
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC).

              Metastatic disease is a major morbidity of prostate cancer (PCa). Its prevention is an important goal. To assess the effect of screening for PCa on the incidence of metastatic disease in a randomized trial. Data were available for 76,813 men aged 55-69 yr coming from four centers of the European Randomized Study of Screening for Prostate Cancer (ERSPC). The presence of metastatic disease was evaluated by imaging or by prostate-specific antigen (PSA) values >100 ng/ml at diagnosis and during follow-up. Regular screening based on serum PSA measurements was offered to 36270 men randomized to the screening arm, while no screening was provided to the 40543 men in the control arm. The Nelson-Aalen technique and Poisson regression were used to calculate cumulative incidence and rate ratios of M+ disease. After a median follow-up of 12 yr, 666 men with M+ PCa were detected, 256 in the screening arm and 410 in the control arm, resulting in cumulative incidence of 0.67% and 0.86% per 1000 men, respectively (p<0.001). This finding translated into a relative reduction of 30% (hazard ratio [HR]: 0.70; 95% confidence interval [CI], 0.60-0.82; p=0.001) in the intention-to-screen analysis and a 42% (p=0.0001) reduction for men who were actually screened. An absolute risk reduction of metastatic disease of 3.1 per 1000 men randomized (0.31%) was found. A large discrepancy was seen when comparing the rates of M+ detected at diagnosis and all M+ cases that emerged during the total follow-up period, a 50% reduction (HR: 0.50; 95% CI, 0.41-0.62) versus the 30% reduction. The main limitation is incomplete explanation of the lack of an effect of screening during follow-up. PSA screening significantly reduces the risk of developing metastatic PCa. However, despite earlier diagnosis with screening, certain men still progress and develop metastases. The ERSPC trial is registered under number ISRCTN49127736. Copyright © 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved.
                Bookmark

                Author and article information

                Journal
                Asia Pac J Oncol Nurs
                Asia Pac J Oncol Nurs
                APJON
                Asia-Pacific Journal of Oncology Nursing
                Medknow Publications & Media Pvt Ltd (India )
                2347-5625
                2349-6673
                Oct-Dec 2017
                : 4
                : 4
                : 348-355
                Affiliations
                [1 ]Department of Adult Health and Critical Care, College of Nursing, Sultan Qaboos University, Al Khod, Muscat, Oman
                [2 ]Department of Community and Mental Health, College of Nursing, Sultan Qaboos University, Al Khod, Muscat, Oman
                Author notes
                Corresponding author: Joshua K. Muliira Department of Adult Health and Critical Care, College of Nursing, Sultan Qaboos University, Muscat, Oman Tel: +968-932-84347; Fax: +966-244-13536 E-mail: jkmuliira@ 123456gmail.com
                Article
                APJON-4-348
                10.4103/apjon.apjon_34_17
                5559947
                28966965
                6eef6af9-7fa2-4fbf-b8b6-52d04bbe51ea
                Copyright: © 2017 Ann & Joshua Medical Publishing Co. Ltd

                This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

                History
                : 13 September 2016
                : 18 October 2016
                Categories
                Original Article

                cancer screening,early diagnosis,men,oman,prevention,prostate cancer

                Comments

                Comment on this article